JNJ-79032421

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JNJ-79032421, covering 2025-07-20 to 2025-07-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors [Phase 1]